Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma

• Published in: Neuro-oncology advances 2022-11, Vol.4 (Suppl 2), p.ii33-ii40
• Main Authors: Friedman, Joshua S, Hertz, Charli Ann J, Karajannis, Matthias A, Miller, Alexandra M
• Format: Article
• Language: English
• Subjects: Supplement
• ISSN: 2632-2498; 2632-2498
• DOI: 10.1093/noajnl/vdac034

Liquid biopsy has emerged as a novel noninvasive tool in cancer diagnostics. While significant strides have been made in other malignancies using liquid biopsy for diagnosis, disease monitoring, and treatment selection, development of these assays has been more challenging for brain tumors. Recently, research in primary and metastatic brain tumors has begun to harness the potential utility of liquid biopsy-particularly using circulating tumor DNA (ctDNA). Initial studies to identify ctDNA in plasma of brain tumor patients have shown feasibility, but the yield of ctDNA is far below that for other malignancies. Attention has therefore turned to the cerebrospinal fluid (CSF) as a more robust source of ctDNA. This review discusses the unique considerations in liquid biopsy for glioma and places them in the context of the work to date. We address the utility of CSF liquid biopsy for diagnosis, longitudinal monitoring, tracking tumor evolution, clinical trial eligibility, and prognostication. We discuss the differences in assay requirements for each clinical application to best optimize factors such as efficacy, cost, and speed. Ultimately, CSF liquid biopsy has the potential to transform how we manage primary brain tumor patients.